Prudential Financial
IMDX

Prudential Financial’s Insight Molecular Diagnostics IMDX Stock Holding History

Prudential Financial’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-720
Closed -$21K – 2730
2022
Q1 		$21K Sell
720
-4,160
-85% -$133K ﹤0.01% 2585
2021
Q4 		$212K Buy
4,880
+2,354
+93% +$135K ﹤0.01% 2527
2021
Q3 		$180K Buy
+2,526
New +$232K ﹤0.01% 2490
2021
Q1 		– Sell
-779
Closed -$37K – 2523
2020
Q4 		$37K Hold
779
– – ﹤0.01% 2417
2020
Q3 		$22K Buy
+779
New +$22.3K ﹤0.01% 2417

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

Prudential Financial's IMDX Position: Q2 2022 in Review

Prudential Financial sold out of Insight Molecular Diagnostics (IMDX) in Q2 2022, closing a stake of 720 shares — an estimated $21K sold.

Prudential Financial first reported a position in IMDX in Q3 2020 and held it in 5 quarters. The position peaked at $212K in Q4 2021. 75 funds tracked by Wall St. Rank hold IMDX as of Q2 2022.

  • Prudential Financial reported no remaining Insight Molecular Diagnostics position as of Q2 2022 after selling out during the quarter.
  • Prudential Financial sold 720 Insight Molecular Diagnostics shares in Q2 2022, an estimated $21K.
  • Prudential Financial first reported a position in Insight Molecular Diagnostics in Q3 2020 and held it in 5 quarters.
  • Prudential Financial's Insight Molecular Diagnostics position peaked at $212K in Q4 2021.
  • 75 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2022.

Based on Prudential Financial's 13F filing for Q2 2022, filed 15 Aug 2022.